Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Rosell

Showing results (161-170 of 470) with videos related to

Pageof 47
Sort By:
Therapeutic Advances in Medical Oncology|April 12, 2018
STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancerIlaria Attili, Niki Karachaliou, Laura Bonanno, et al.
Archives of Pathology & Laboratory Medicine|March 23, 2018
RNA Analysis as a Tool to Determine Clinically Relevant Gene Fusions and Splice VariantsCristina Teixidó, Ana Giménez-Capitán, Miguel Ángel Molina-Vila, et al.
Clinical Lung Cancer|August 16, 2005
Wnt signaling in stem cells and non-small-cell lung cancerBiao He, Richard N Barg, Liang You, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2010
No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysisMing Yin, Jingrong Yan, Alexandra Voutsina, et al.
International Journal of Cancer|September 30, 2010
Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancerAbel Sanchez-Palencia, Mercedes Gomez-Morales, Jose Antonio Gomez-Capilla, et al.
Translational Lung Cancer Research|January 23, 2016
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicitySara Pilotto, Miguel Angel Molina-Vila, Niki Karachaliou, et al.
Lung Cancer (Amsterdam, Netherlands)|August 22, 2009
Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?Mariano Provencio, Ramón de Las Peñas, Carlos Camps, et al.
Expert Opinion on Investigational Drugs|May 3, 2017
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancerNiki Karachaliou, Mariacarmela Santarpia, Maria Gonzalez Cao, et al.
Biomed Research International|April 8, 2014
TAZ is highly expressed in gastric signet ring cell carcinomaGuofeng Yue, Xia Sun, Ana Gimenez-Capitan, et al.
Clinical Lung Cancer|September 3, 2011
Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancerRafael Rosell, Christian Manegold, Teresa Moran, et al.
Pageof 47

Showing results (161-170 of 470) with videos related to

Sort By:
Pageof 47
Therapeutic Advances in Medical Oncology|April 12, 2018
STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancerIlaria Attili, Niki Karachaliou, Laura Bonanno, et al.
Archives of Pathology & Laboratory Medicine|March 23, 2018
RNA Analysis as a Tool to Determine Clinically Relevant Gene Fusions and Splice VariantsCristina Teixidó, Ana Giménez-Capitán, Miguel Ángel Molina-Vila, et al.
Clinical Lung Cancer|August 16, 2005
Wnt signaling in stem cells and non-small-cell lung cancerBiao He, Richard N Barg, Liang You, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2010
No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysisMing Yin, Jingrong Yan, Alexandra Voutsina, et al.
International Journal of Cancer|September 30, 2010
Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancerAbel Sanchez-Palencia, Mercedes Gomez-Morales, Jose Antonio Gomez-Capilla, et al.
Translational Lung Cancer Research|January 23, 2016
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicitySara Pilotto, Miguel Angel Molina-Vila, Niki Karachaliou, et al.
Lung Cancer (Amsterdam, Netherlands)|August 22, 2009
Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?Mariano Provencio, Ramón de Las Peñas, Carlos Camps, et al.
Expert Opinion on Investigational Drugs|May 3, 2017
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancerNiki Karachaliou, Mariacarmela Santarpia, Maria Gonzalez Cao, et al.
Biomed Research International|April 8, 2014
TAZ is highly expressed in gastric signet ring cell carcinomaGuofeng Yue, Xia Sun, Ana Gimenez-Capitan, et al.
Clinical Lung Cancer|September 3, 2011
Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancerRafael Rosell, Christian Manegold, Teresa Moran, et al.
Pageof 47